131 related articles for article (PubMed ID: 29848725)
1. The Role of Interleukin-6 Polymorphism (rs1800795) in Prostate Cancer Development and Progression.
Jurečeková J; Drobková H; Šarlinová M; Babušíková E; Sivoňová MK; Matáková T; Kliment J; Halašová E
Anticancer Res; 2018 Jun; 38(6):3663-3667. PubMed ID: 29848725
[TBL] [Abstract][Full Text] [Related]
2. An Interleukin-6 Single Nucleotide Polymorphism and Susceptibility to Prostate Adenocarcinoma and Bone Metastasis in an Iranian Population.
Dargahi Abbasabad G; Banan Khojasteh SM; Eskandari Naji H; Zamani MR; Hajipour H; Serati-Nouri H
Asian Pac J Cancer Prev; 2018 Jun; 19(6):1717-1720. PubMed ID: 29938471
[TBL] [Abstract][Full Text] [Related]
3. Role of interleukin-6 gene polymorphisms in the development of prostate cancer.
Chen CH; Gong M; Yi QT; Guo JH
Genet Mol Res; 2015 Oct; 14(4):13370-4. PubMed ID: 26535651
[TBL] [Abstract][Full Text] [Related]
4. Association between interleukin-18 variants and prostate cancer in Slovak population.
Jurecekova J; Babusikova E; Kmetova Sivonova M; Drobkova H; Petras M; Kliment J; Halasova E
Neoplasma; 2017; 64(1):148-155. PubMed ID: 27881017
[TBL] [Abstract][Full Text] [Related]
5. Interleukins-6 -174G/C (rs1800795) and -572C/G (rs1800796) polymorphisms and prostate cancer risk.
Iqbal MS; Peng K; Sardar N; Iqbal MH; Ghani MU; Tanvir F; Gu D; Guohua Z; Duan X
Mol Immunol; 2023 Dec; 164():88-97. PubMed ID: 37989067
[TBL] [Abstract][Full Text] [Related]
6. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect.
Habuchi T; Liqing Z; Suzuki T; Sasaki R; Tsuchiya N; Tachiki H; Shimoda N; Satoh S; Sato K; Kakehi Y; Kamoto T; Ogawa O; Kato T
Cancer Res; 2000 Oct; 60(20):5710-3. PubMed ID: 11059764
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-converting enzyme insertion/deletion and angiotensin type 1 receptor A1166C polymorphisms as genetic risk factors in benign prostatic hyperplasia and prostate cancer.
Sierra Díaz E; Sánchez Corona J; Rosales Gómez RC; Gutierrez Rubio SA; Vázquez Camacho JG; Solano Moreno H; Morán Moguel MC
J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):241-6. PubMed ID: 20026870
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6 polymorphism is associated with more aggressive prostate cancer.
Tan D; Wu X; Hou M; Lee SO; Lou W; Wang J; Janarthan B; Nallapareddy S; Trump DL; Gao AC
J Urol; 2005 Aug; 174(2):753-6. PubMed ID: 16006970
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-6 promoter polymorphism and plasma levels in patients with schizophrenia.
Zakharyan R; Petrek M; Arakelyan A; Mrazek F; Atshemyan S; Boyajyan A
Tissue Antigens; 2012 Aug; 80(2):136-42. PubMed ID: 22571276
[TBL] [Abstract][Full Text] [Related]
10. Alpha 1 antichymotrypsin genotype is associated with increased risk of prostate carcinoma and PSA levels.
Licastro F; Bertaccini A; Porcellini E; Chiappelli M; Pernetti R; Sanguedolce F; Marchiori D; Martorana G
Anticancer Res; 2008; 28(1B):395-9. PubMed ID: 18383875
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population.
Ma Z; Tsuchiya N; Yuasa T; Inoue T; Kumazawa T; Narita S; Horikawa Y; Tsuruta H; Obara T; Saito M; Satoh S; Ogawa O; Habuchi T
Int J Cancer; 2008 Dec; 123(11):2574-9. PubMed ID: 18756523
[TBL] [Abstract][Full Text] [Related]
12. Association of elevated interleukin-33 serum levels with tumorstages in patients with prostate cancer.
Chatrabnous N; Jafarzadeh A; Ghaderi A; Ariafar A; Aminizadeh N; Ghassabi F; Nemati M
Eur Cytokine Netw; 2019 Dec; 30(4):144-150. PubMed ID: 32096476
[TBL] [Abstract][Full Text] [Related]
13. IL-6 Genomic Variants and Risk of Prostate Cancer.
Taheri M; Noroozi R; Rakhshan A; Ghanbari M; Omrani MD; Ghafouri-Fard S
Urol J; 2019 Oct; 16(5):463-468. PubMed ID: 30345492
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-6 polymorphism and prostate cancer risk in population of Eastern Croatia.
Mandić S; Sudarević B; Marczi S; Horvat V; Cosić I; Mihaljević S; Milicević N; Simunović D; Galić J
Coll Antropol; 2013 Sep; 37(3):907-11. PubMed ID: 24308236
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-6 -572G/C polymorphism and prostate cancer susceptibility.
Huang WJ; Wu LJ; Min ZC; Xu LT; Guo CM; Chen ZP; Lou XJ; Xu B; Lv BD
Genet Mol Res; 2016 Sep; 15(3):. PubMed ID: 27706719
[TBL] [Abstract][Full Text] [Related]
16. Genetic Polymorphism of MMP2 Gene and Susceptibility to Prostate Cancer.
Adabi Z; Mohsen Ziaei SA; Imani M; Samzadeh M; Narouie B; Jamaldini SH; Afshari M; Safavi M; Roshandel MR; Hasanzad M
Arch Med Res; 2015 Oct; 46(7):546-50. PubMed ID: 26319608
[TBL] [Abstract][Full Text] [Related]
17. Strong association of interleukin-6 -174G/C promoter single nucleotide polymorphism with a decreased risk of colorectal cancer in ethnic Kashmiri population: A case control study.
Banday MZ; Balkhi HM; Sameer AS; Chowdri NA; Haq E
Tumour Biol; 2017 Mar; 39(3):1010428317695940. PubMed ID: 28349833
[TBL] [Abstract][Full Text] [Related]
18. Association of G/A polymorphism, rs266882, in AREI region of the prostate-specific antigen gene with prostate cancer risk and clinicopathological features.
Samzadeh M; Hasanzad M; Jamaldini SH; Haghdoost AA; Afshari M; Ziaee SA
Urol J; 2012; 9(4):691-9. PubMed ID: 23235975
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6 promoter variants, prostate cancer risk, and survival.
Tindall EA; Severi G; Hoang HN; Southey MC; English DR; Hopper JL; Giles GG; Hayes VM;
Prostate; 2012 Dec; 72(16):1701-7. PubMed ID: 22782910
[TBL] [Abstract][Full Text] [Related]
20. The impact of interleukin-10 (IL-10) gene 4 polymorphisms on peripheral blood IL-10 variation and prostate cancer risk based on published studies.
Men T; Yu C; Wang D; Liu F; Li J; Qi X; Yang C; Jiang W; Wei X; Li X; Wang B; Mi J; Tian G
Oncotarget; 2017 Jul; 8(28):45994-46005. PubMed ID: 28526808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
